Retatrutide: Two Appetite Arms and a Third Lever

The short version

Retatrutide is one molecule that switches on three different receptors at the same time. Two of them — GLP-1 and GIP — belong to the gut-hormone system that signals fullness after a meal. The third, the glucagon receptor, does something different: it raises the amount of energy the body spends and mobilises stored fat.

That combination is the whole idea. Appetite suppression reduces what goes in; the glucagon arm increases what goes out. In a 48-week Phase 2 trial, the highest dose produced a mean body-weight change of -24.2% against -2.1% with placebo ^[11].

It is not an approved medicine anywhere. It has completed Phase 2 trials and is in Phase 3, which means the long-term safety record, the durability of the weight change after stopping, and the cardiovascular and kidney outcomes are all genuinely unknown rather than merely unpublished.

The third arm also has a visible cost: heart rate rose in a dose-dependent way in the same trials ^[11].

What it is

Class. GIP/GLP-1/glucagon receptor triple agonist — an investigational anti-obesity and anti-diabetic peptide, catalogued in the literature as LY3437943.

Structure. A 39-amino-acid synthetic peptide built on a GIP-based backbone and acylated with a C20 fatty di-acid. The acyl chain performs the same job it does in the rest of this class: it binds serum albumin, slows clearance, and converts a hormone that would be cleared in minutes into a molecule suitable for weekly administration.

Regulatory status. Investigational. In Phase 3 trials and not approved by the FDA or any other regulator as of this revision, which means every efficacy and safety figure below comes from clinical trials rather than from approved labelling. There is no approved indication, no approved dosing, and no consumer or prescription product.

There is no brand name. Retatrutide is identified in the literature by its compound name and by its development code, LY3437943. Because it is approved nowhere, no brand-name product containing it is marketed anywhere in the world, and anything presented as a retail brand for retatrutide is not one — a useful test to apply to any material encountered under a brand-shaped name.

Anti-doping status. Not specifically named on the WADA Prohibited List as of the current code, though the status of investigational agents is subject to change and athletes are expected to verify it independently.

A gray market in research-labelled material exists outside all of this. Such vials sit outside clinical oversight and outside the evidence base described here, and nothing on this page should be read as characterising them.

How it works: three receptors, two of them satiety

Retatrutide is best understood as the incretin satiety mechanism with an extra lever bolted on.

The appetite arms. GLP-1 receptor agonism does here what it does for any compound in the class: slowed gastric emptying, prolonged fullness, and access to the hypothalamic and brainstem circuits that reduce food intake. GIP receptor agonism contributes to glucose-dependent insulin secretion and, in this class, is understood to add to the appetite effect rather than to work against it.

The expenditure arm. Controlled glucagon receptor activation adds energy expenditure and lipid mobilisation. This is the part that is not a satiety mechanism — it does not make a meal end sooner; it changes the metabolic accounting after the meal. A 2025 review characterises the combination, and the roughly 24% weight reduction it produced in Phase 1 and 2 work, as a step change relative to earlier incretin therapies ^[8].

The receptor pharmacology is counter-intuitive. Cryo-electron microscopy structures resolved retatrutide bound to all three receptors and found it approximately 8.9 times more potent at the GIP receptor than the native hormone, but only 0.3 and 0.4 times as potent at the glucagon and GLP-1 receptors respectively, compared with their endogenous ligands ^[9]. The molecule that produces the largest weight changes in this briefing is therefore a weaker GLP-1 receptor agonist than GLP-1 itself. Balance across three receptors, not raw potency at the satiety receptor, appears to be what the design is optimising.

The cost of the third arm. Glucagon receptor activation drives cardiac chronotropy, and the dose-dependent heart-rate increase seen in Phase 2 is the predictable consequence of the same mechanism that supplies the extra energy expenditure ^[11].

What the research shows

Obesity — 48-week Phase 2. In 338 adults with obesity, or with overweight plus a weight-related comorbidity, once-weekly retatrutide at 12 mg produced a mean body-weight change of -24.2% at 48 weeks against -2.1% with placebo. Gastrointestinal adverse events were dose-related and mostly mild to moderate, and heart rate rose in a dose-dependent fashion, peaking at around 24 weeks ^[11]. This is the headline result for the compound.

Type 2 diabetes — 36-week Phase 2. In 281 adults with type 2 diabetes, retatrutide 12 mg lowered HbA1c by 2.02 percentage points at 24 weeks against 0.01 with placebo, and reduced body weight by 16.94% at 36 weeks against 3.00% with placebo. Mild-to-moderate gastrointestinal adverse events occurred in 35% of participants; no severe hypoglycaemia and no deaths were reported ^[12].

Metabolic liver disease — Phase 2a substudy. Among 98 participants with obesity or overweight and metabolic dysfunction-associated steatotic liver disease with at least 10% liver fat by MRI-PDFF and no type 2 diabetes, retatrutide 12 mg reduced liver fat by 82.4% at 24 weeks against a 0.3% increase with placebo, with 86% of participants reaching normal liver fat below 5%. Reductions were sustained to 48 weeks, reaching 86.0% at the top dose ^[10].

Receptor structure. Cryo-EM structures of retatrutide bound to GLP-1R, GIPR and GCGR were resolved at 2.68, 3.26 and 2.84 angstroms, with relative potencies of 8.9 times native GIP at GIPR, 0.3 times at GCGR and 0.4 times at GLP-1R ^[9].

Synthesis. A 2025 review consolidates the triple-agonist pharmacology, the Phase 1 and 2 efficacy data, the gastrointestinal and heart-rate safety profile, and the ongoing Phase 3 TRIUMPH programme ^[8].

What is conspicuously absent. There are no published long-term outcome data, no completed cardiovascular outcome trial, no completed kidney outcome trial, and no published characterisation of what happens to body weight after treatment stops. Those trials are running, not finished.

Reported effects, cautions, and what to watch

Community reports. The following comes from research-use community discussion. It is anecdotal, not clinical evidence, it carries no doses, and it is unverified self-reporting without clinical oversight.

The most consistent theme is the near-total silencing of intrusive food thoughts — described less as feeling full than as simple disinterest in eating. Weight reduction is frequently described as feeling qualitatively faster than experiences with other compounds in this class. A subset report a distinctive warmth or mild flushing, running warmer or sweating more easily, which community discussion attributes to the glucagon arm, and some describe reduced anxiety around food and a lighter relationship with eating.

On the adverse side, awareness of a faster resting heart rate in the hours after administration is a recurring theme, with some citing wearable data. Nausea in the hours after injection is among the most common reports and is described as easing over subsequent weeks. Sulfur-smelling burps, constipation, and an early-weeks dip in energy — heavy legs, extra sleep, a foggy tiredness — appear repeatedly, as do occasional injection-site itching and difficulty falling or staying asleep. Members who track body composition sometimes describe rapid loss feeling soft and worry about losing muscle alongside fat.

Cautions from the literature. Gastrointestinal adverse events are dose-dependent and were the principal driver of discontinuation in Phase 2, with nausea affecting up to 45% of participants at the highest dose and an 18% discontinuation rate at that dose level ^[11]. Resting heart rate rose dose-dependently, by roughly 5 to 7 beats per minute at the highest doses and peaking around 24 weeks; the implications for anyone with pre-existing arrhythmia or cardiovascular disease are unstudied outside a monitored trial ^[11]. Combined with insulin or sulfonylureas the glucose-lowering effect compounds, and trial participants on background insulin required de-escalation of it — an interaction that without monitoring can produce severe hypoglycaemia ^[12]. Body-composition work shows absolute reductions in lean mass alongside fat mass, which is why protein intake and resistance training are an active research question rather than an afterthought. Long-term safety, durability after discontinuation, and cardiovascular and renal outcomes are all unresolved while the pivotal trials run ^[8]. Finally, material obtained outside a clinical trial has no verified identity, concentration, purity or sterility, and regulatory action against vendors selling research-labelled retatrutide has been documented.

Where it sits in the satiety picture

Retatrutide is the compound that tests whether satiety is the whole story. Both of its incretin arms do what semaglutide does — occupy the appetite signal and hold it open. The glucagon arm then adds a lever that has nothing to do with feeling full, and the reported weight changes are the largest in this briefing ^[11][8].

Read structurally, the case is stronger still: it is a weaker GLP-1 receptor agonist than the native hormone ^[9] and it still outperforms single-arm agonism in separate trials. That is difficult to explain in a purely satiety-driven model and easy to explain in an intake-plus-expenditure model.

The trade is visible in the same data. The mechanism that raises expenditure also raises heart rate, dose-dependently ^[11]. And the evidence tier is not comparable: semaglutide has completed cardiovascular and kidney outcome trials in tens of thousands of participants, while retatrutide's equivalents are ongoing. The largest effect size in this briefing sits on the shortest record — that pairing is the single most important thing to hold in mind about it.